Letrozol Jgl 2,5 Mg

Letrozole, the active ingredient in Letrozol Jgl 2,5 Mg, is an aromatase inhibitor presented as a 2.5 mg tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Jgl 2,5 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Letrozole is an aromatase inhibitor used in the management of hormone‑dependent breast cancer. - Hormone receptor‑positive breast cancer: reduces tumor growth in postmenopausal women. - Adjuvant therapy for early‑stage disease: lowers risk of recurrence after surgery. - Metastatic breast cancer: prolongs progression‑free survival in advanced disease.

Letrozole may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in limbs or back. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Osteoporosis or bone loss: increased fracture risk. - Cardiovascular events: hypertension, thromboembolism. - Liver function abnormalities: elevated enzymes or hepatitis. - Severe allergic reactions: rash, swelling, anaphylaxis. - Pulmonary embolism: sudden shortness of breath. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Bone health assessment: perform baseline densitometry and consider calcium/vitamin D supplementation. - Liver function monitoring: check transaminases periodically. - Cardiovascular risk review: assess blood pressure and lipid profile. - Pregnancy avoidance: letrozole is contraindicated in pregnancy (Category X). - Hepatic impairment caution: dose adjustment may be required in severe liver disease. - Storage at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines that affect its metabolism or hormonal pathways.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase letrozole exposure. - Estrogen‑containing hormone therapy: antagonizes letrozole’s effect. - Certain antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant control. - Statins: potential for increased muscle toxicity. - SSRIs and SNRIs: possible additive effects on mood or fatigue. - Glucocorticoids: may affect bone health when combined. - NSAIDs: monitor for gastrointestinal irritation.